Archives: Agenda

From trials to continuous oncology intelligence: Do we still need clinical trials in 2040? How AI, Synthetic Evidence, and living data are rewiring the cancer lifecycle

  • Synthetic populations and AI-simulated control arms are already reducing reliance on traditional randomization
  • Real-time, adaptive approval models could replace rigid phase boundaries
  • Continuous post-market learning may become as important as pre-market proof
  • Decision-making authority shifts as AI accelerates evidence generation beyond human-paced review cycles

Reimagining the oncology patient journey: From protocol design to real-time, decision-driven trials

  • Shift trial success toward speed and quality of decisions, not just endpoints, by embedding patient journey insights early.
  • Enable precision enrollment and site activation through integrated data (EHR, genomics, biomarkers) and real-time feasibility.
  • Use Biomarkers/MRD/ctDNA and real-time data flows to drive adaptive treatment decisions and improve patient outcomes.
  • Operate within a connected partner ecosystem (sponsor-CRO-diagnostics) to deliver faster, more reliable, decision-grade evidence.

Putting sites first in early oncology: What integrated site networks are telling us

  • Understanding the operational challenges, enrollment barriers, and patient engagement realities facing oncology sites today
  • Examining how stronger collaboration between sponsors, CROs, and sites can improve study execution and reduce operational risk
  • Identifying practical site-first approaches that accelerate start-up, enhance recruitment, and support patient retention
  • Exploring how integrated site networks can help deliver more efficient, patient-centric early phase oncology trials from planning through execution

KEYNOTE: Redefining eligibility in oncology trials: Ancestry-aware design for biologically valid and globally relevant drug approval

  • Recognizing how the geographic concentration of oncology trials can limit the global relevance of regulatory evidence
  • Understanding the role of genomic and epigenomic variation across ancestries in driving treatment response and toxicity
  • Identifying how environmental and contextual factors interact with biology to influence therapeutic outcomes
  • Evaluating how conventional eligibility criteria may exclude biologically relevant patient populations
  • Learning the principles of ancestry-aware eligibility design as a scientifically rigorous approach to trial inclusion
  • Assessing how eligibility reform can improve the predictive validity of clinical trial data for regulators and sponsors
  • Applying ancestry-aware trial design concepts to support equitable, efficient, and globally applicable drug approvals

Four studies, one year: The case for building your oncology engine in Europe

  • Challenging the perception of Europe as a backup option for oncology trials rather than a strategic development partner
  • Sharing practical lessons from running four concurrent Phase II oncology studies across Europe, with a strong focus on Poland
  • Examining the operational, recruitment, and cost advantages that can make Europe a compelling choice for clinical-stage biotechs
  • Highlighting what worked, what didn’t, and the key considerations sponsors should evaluate before defaulting to traditional trial geographies
  • Exploring how early integration of European sites can strengthen global development strategies and accelerate clinical progress

Finding the perfect match: Selecting and supporting the right oncology sites in an increasingly competitive landscape by rethinking selection, readiness and partnerships

  • Overcoming site readiness challenges through targeted education, certification, and operational support, ensuring sites are equipped and committed from day one
  • Competing smarter in a crowded oncology landscape by making your trial more attractive to sites through simplified protocols, better support, and stronger partnerships
  • Moving beyond traditional site selection to identify truly trial-ready sites, assessing infrastructure, staff capacity, competing studies, and long-term engagement potential
  • Redefining sponsor–site collaboration with more flexible, locally informed strategies that prioritize feasibility, performance, and sustainable site relationships
  • Addressing the growing divide between academic and community sites, and unlocking new models to expand access, improve recruitment, and reduce site drop-off

 

From protocol design to operational reality: Making clinical trials work before they start

  • Transforming Protocol to Execution: How AIKA uses advanced AI to streamline protocol generation, enhance feasibility analysis, and reduce study start-up timelines.
  • Data-Driven Decision Support: Leveraging real-time operational insights and predictive analytics to improve trial performance and risk mitigation.
  • Scaling Clinical Operations: Practical examples of AIKA in action, from automated task orchestration to cross-functional collaboration that drives efficiency and quality.